|
 |
|
Drug Safety Newsletter on Antivirals
Date: 02 September 2009 The IMB has published a Drug Safety Newsletter on the antiviral medicines Tamiflu and Relenza, which provides an overview of relevant regulatory activities and associated recommendations for safe use of these medicines. Click here to download.
The IMB has developed a web-based system for reporting of adverse reactions by healthcare professionals, patients and the public during the pandemic. This is accessible via a designated ‘pandemic webpage' on the IMB website at http://www.imb.ie/EN/Medicines/Pandemic-H1N1-2009.aspx.
Please use the contact details below with any queries you may have in relation to the newsletter or the reporting of adverse reactions:
Tel: 353-1-676 4971
Fax: 353-1-634 3514
Email: imbpharmacovigilance@imb.ie
Pharmacovigilance Section,
Irish Medicines Board,
Kevin O'Malley House,
Earlsfort Centre,
Earlsfort Terrace,
Dublin 2,
Ireland.
|
| |
|
|
|
![[LINK WILL OPEN NEW WINDOW] Level A conformance icon, W3C-WAI Web Content Accessibility Guidelines 1.0](../../sitedesign/images/w3c_wcag1A.gif){kind=small}
![[LINK WILL OPEN NEW WINDOW] Valid XHTML 1.0!](../../sitedesign/images/w3c_vxhtml10.gif){kind=small}
![[LINK WILL OPEN NEW WINDOW] Valid CSS !](../../sitedesign/images/w3c_vcss.gif){kind=small}